Lupin gets US FDA EIR with satisfactory VAI for Nagpur injectables plant

Regulatory & Legal View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹2085.90

prior close

₹2100.90

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.5%+1.9% vs market

Pharmaceuticals peers, median of 156sector-0.8%+2.2% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.9

15m

+0.7

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-0.5+1.9-0.8+2.2

Next day

+1.4-0.3+1.8-1.0+2.4

+1.8+0.8+1.0-0.1+1.9

+2.2+1.7+0.5+0.2+1.9

+1.1+1.8-0.7+0.5+0.6

+0.9+1.3-0.4+0.0+0.9

-0.2+0.6-0.8-0.9+0.7

15d

+5.1+1.0+4.1-0.4+5.5

+4.5-0.4+4.9-3.7+8.1

+7.6+0.3+7.2-3.7+11.3

+10.3-7.3+17.5-11.3+21.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Limited received an Establishment Inspection Report (EIR) from the US FDA for its injectables facility in Nagpur, India, classified as Voluntary Action Indicated (VAI) — a satisfactory outcome meaning no regulatory action is needed. The EIR follows an FDA inspection held from September 8 to 16, 2025. Managing Director Nilesh Gupta said the company remains committed to quality and compliance across all facilities.

Likely market impact

Positive for shareholders — clears regulatory uncertainty on the Nagpur plant and strengthens confidence in Lupin's US injectables business.